retatrutide obesity phase 2 trial Eli Lilly infiltrates anti-obesity market as III for begins Retatrutide: What the Liver-Fat and

They defined GLP-1 agonist use as a documented prescription for GLP-1 before the breast imaging examination

Importantly, this reduction in loading coincided with significant declines in BMD at the total hip ( 7.0%), femoral neck ( 8.8%), and lumbar spine ( 5.2%)

Although a trend toward reduced HCC risk was observed, this failed to achieve statistical significance in the overall analysis (IRR: 0.82, 95%CI: 0.61-1.11, P = 0.189), possibly reflecting insufficient follow-up duration to capture the full impact on hepatocarcinogenesis

Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial

Body mass index (BMI) is a simple tool to estimate a persons body fat content based on their height and weight